A 52-year-old man is evaluated for low back pain of 3 months’ duration that is nonradiating, progressive, and worse with ambulation. He reports no preceding injury. Medical history is notable for smoldering multiple myeloma diagnosed 1 year ago; he has been stable since that time. His only medication is as-needed acetaminophen.
On physical examination, temperature is 36.8 °C (98.2 °F), blood pressure is 132/82 mm Hg, pulse rate is 70/min, and respiration rate is 14/min. No focal neurologic findings are noted. He has pain to palpation of the lower lumbar spine. The remainder of the examination is unremarkable.
Laboratory studies show a hemoglobin level of 13 g/dL (130 g/L), serum creatinine level of 1.0 mg/dL (88.4 µmol/L), and serum calcium level of 9.8 mg/dL (2.5 mmol/L).
Plain radiographs of the lumbosacral spine demonstrate degenerative disk changes in the lumbar spine but no lytic lesions or fractures.
Which of the following is the most appropriate management?
A: Chemotherapy
B: MRI of the lumbar spine
C: Symptomatic treatment and routine follow-up
D: Zoledronic acid
MKSAP Answer and Critique
The correct answer is B: MRI of the lumbar spine.
This patient should undergo MRI of the lumbar spine. He has a diagnosis of smoldering (asymptomatic) multiple myeloma, which is defined as an M protein level of 3 g/dL or more or clonal plasma cells representing 10% or more of the total marrow cellularity on bone marrow biopsy but the absence of disease-specific signs or symptoms. Most patients with smoldering myeloma eventually develop symptomatic disease, with a median time to progression of 4.8 years. Therefore, surveillance in these patients is necessary. The CRAB (hyperCalcemia, Renal failure, Anemia, Bone disease) criteria for a diagnosis of multiple myeloma requiring therapy are commonly used to determine the need to start chemotherapy. Although this patient does not have hypercalcemia, kidney disease (renal failure), or anemia, he is experiencing unexplained lower back pain with nonspecific findings on plain radiographic imaging. Therefore, additional imaging is warranted to better determine the cause of the pain. Although plain radiography remains an important component of the initial evaluation of patients with multiple myeloma, more than 30% of trabecular bone must be lost before lytic lesions are evident by plain radiographs. MRI is a more sensitive imaging modality for detecting lytic bone lesions of myeloma, and would be the preferred next imaging study in this patient. Additional imaging techniques that may be used in multiple myeloma include CT or PET/CT.
The role of chemotherapy in patients with smoldering myeloma is unclear. Although lenalidomide and dexamethasone have been shown to delay disease progression, the optimal patient population for these agents has not been identified, and early initiation of chemotherapy for smoldering myeloma is not routinely utilized.
Although most patients with acute low-back pain may be treated conservatively without imaging, symptomatic treatment of this patient’s low back pain with routine follow-up would not be appropriate because of his diagnosis of multiple myeloma and the possibility that his back pain is secondary to disease progression.
Bisphosphonates are a key component of therapy for patients with multiple myeloma requiring therapy. Zoledronic acid has been shown to reduce the risk of skeletal-related events and improve progression-free survival. However, the patient has yet to be diagnosed with symptomatic myeloma. No role exists for the routine use of bisphosphonates for patients with smoldering myeloma.
Key Point
- An MRI or CT is more sensitive at detecting lytic bone lesions than plain radiographs in patients with multiple myeloma and should be considered when bone pain is present and plain radiographs are unrevealing.
This content is excerpted from MKSAP 17 with permission from the American College of Physicians (ACP). Use is restricted in the same manner as that defined in the MKSAP 16 Digital license agreement. This material should never be used as a substitute for clinical judgment and does not represent an official position of ACP. All content is licensed to KevinMD.com on an “AS IS” basis without any warranty of any nature. The publisher, ACP, shall not be liable for any damage or loss of any kind arising out of or resulting from use of content, regardless of whether such liability is based in tort, contract or otherwise.
